Von Euw et al. [10] concluded from their data that there is a reproducible increase in IL-17-producing cells among activated blood cells after the administration of tremelimumab, another CTLA-4 blocker, suggesting an increase in Th17 cells with CTLA-4 blockade in patients with metastatic melanoma. Here, IL17A is linked to metastatic melanoma.